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Abstract To study specific properties of the human gamma- 
interferon (?.IFN) receptor-like proteins of the highly virulent 
and low virulent strains of variola (smallpox) virus (VAR) 
recombinant plasmids determining synthesis of these proteins in 
E. to//cells have been constructed. The recombinant viral y.IFN 
receptor-like pruteins have been found to have high interferun- 
neutrallsing activity with regards to human ?.IFN but not marine 
?-IFN and human c~-IFN. The varinla major and varioin minor 
proteins under study do not differ in the efficiency of human 
y-IFN antiviral activity Inhibition. 
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1. Introduction 
Studies of structure-function genome organisation of differ- 
ent representatives of the Poxviridae family and their com- 
parative analysis allow to predict certain functions of proteins 
being coded by these or those open reading frames (ORFs) [1]. 
To reveal genes responsible for overcoming both specific and 
non-specific protective mechanisms of the host organism, is of 
special interest. 
Computer analysis of the variola virus DNA nu¢leotide 
sequence nabled us to reveal in the genome of this virus 
ORFs determining the homologues of soluble receptors of 
the key cytokines uch as y-IFN and tumour necrosis factor 
[1,2]. A hypothesis was put forward that these proteins, to- 
gether with some other ones, mainl~ contribute to the mani- 
festation of VAR's pathogenic properties as well as to success- 
ful overcoming by the virus of the protective mechanisms of 
the human organism [3]. Since laboratory animals ensitive to 
VAR are absent, it is not possible to directly estimate the 
contribution of the genes revealed to the virulence rate of 
this virus. Therefore, a necessary step with regard to verifica- 
tion of this hypothesis is to create producers of such viral 
proteins, isolate these proteins individually and study their 
specific activity. 
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The objective of this work is to create E. coil strains capable 
of producing a mature form of the VAR ¥-IFN receptor-like 
protein and to study its ability to inhibit the antiviral activity 
of both human and murine ¥-IFN. As a source for the target 
B9R gene (Fig. I) [1,2] DNA fragments of the highly virulent 
India-1967 (IND) strain of VAR (variola major) [4] and low 
virulent Garcia-1966 (GAR) strain of VAR (variola minor) [5] 
which were cloned in bacterial plasmids [6] were used. 
High level production of the y-IFN receptor-like protein of 
VAR has been demonstrated in E. coli cells. This recombinant 
viral protein can effectively inhibit the antiviral activity of 
human y-IFN but fails to do so with regard to murine y- 
IFN and human a.IFN. The Variola major and Variola min- 
or proteins under study do not differ in the efficiency of hu- 
man y-IFN antiviral activity inhibition. 
2. Materials and methods 
2. i. Bacteria strains and cell cultures 
In the work E. coil strains were used: JMI03 (A(lac-pro), thi, strA, 
endA, sbcg hsdR-, supEo F'traD36, proAB, iaclqZ.M15); JMI09 
(A(lac-proAB), thi, endAl, hsdRlT, fecAl, gyrA96, supE44, ~.-, 
relAl, FtraD36, proAB, laclqZ-MlS); BL21 (F-, ompT, hsdSa); 
VLI201 (htpR~, supC, strA); VL1222 (htl:R~n, supC, Ion). 
The following cell cultures were used: diploid fibroblasts oflung of 
human embryo L-68 and murine fibroblasts LQ2~. 
2.2. Enzynw~ and chemicals 
Enzymes aad chemicals that were used were: restriction endona- 
cleases, 1'4 DNA ligase, T4 polynucleotide kinase produced either by 
SibEnzyme {Novosibirsk, Russia) or NPO Felmentas (Viinius, 
Lithuania~, mitomycin C, human recombinant y-IFN and murine re- 
combinan~ IFN (Sigma, USA), [¥-32P]ATP (I,000-4,000 Ci/mmol) 
produced by Isotope (Tashkent, Usbekistan), oligonucleotides pro- 
duced by Vector-BioProduct (Koltsovo, Novosibirsk Region, Russia), 
human recombinant a-IFN produced by SRC VB Vector (Koltsovo, 
Novosibi~k Region, Russia). 
2.:?. Plasr~id construction 
Preparation ofmedia, enzymatic reactions, polyacrylamide gelelec- 
trophoresis (PAGE), and E. coil cells transformation were performed 
as described [7]. The DNA fragments with genes of the target proteins 
were obtained from recombinant plasmids bearing extended VAR 
genome segments which included the B9R ORF. As regards the 
IND strain, the AsulI-SalGl fragment with the target ORF was iso- 
lated; as regards the GAR strain, the AsulI-Xhol fragment with the 
corresponding ORF was isolated. 
As expression vector, a pRTU1 plasmid, constructed by us, was 
used. To construct the recombinant pRIRgT and pRIRinT plasmids, 
the E. coli JMI09 cells were transformed bya mixture consisting of 
0.4 pmol pRTUllEcoRI-SalGl, 4 pmol of the corresponding Asull- 
SaiGl (for IND) or Asull-Xhol (for GAR) fragment with the target 
viral ORF and 12 pmol of the phosphorylated synthetic L oRI-Asull 
DNA duplex after ligase reaction (Fig. 2). The clones obtained were 
analysed hy hybridisation with the a2P-labelled oligonucleotide, which 
was used as probe, of the synthetic duplex' upper chain and by re- 
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striction enzyme hydrolysis. From 10 clones (5 for each ORF) which 
met all requirements, plasmids were isolated and the E. coil JMI03 
cells were transformed. The pRIRsT and pRIRmT plasmids that pro- 
vided for the highest viral proteins production rate in the/~ coil cells 
were selected by electrophoretic analysis. The plasmids of those clones 
were isolated and analysed by restriction enzymes hydrolysis, and then 
used for transformation of the other strains of E. coli in order to 
achieve the maximum efficient viral proteins expression. 
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2.4. Recombinant proteins isolation 
The producer strains were cultured and the target recombinant 
proteins ynthesis induced as described earlier [8]. 
The recombinant proteins were isolated from the cellular biomass 
as follows. The cells were destroyed in an ultrasonic disintegrator and 
thus a fraction of non-soluble inclusion bodies was obtained as de- 
scribed [8]. Inclusion bodies were consecutively washed with 1% solu- 
tion of Triton X-100, 2 M and 4 M carbomide prepared in PBS buffer 
[7] while the precipitate was collected by centrifugation. The precipi- 
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Fig, I, Alignment of' nu¢leotide and amino acid sequences of' the FL~R gene of" the India-1967 (IND) and Garcia.1966 (GAR) strains of VAR. 
In the sequence of IND, nucleotides identical to those of GAR are marked with dots. In sequences of the B9R protein, amino acid residues 
which are different in IND and GAR are marked with circles. Horizontal line marks the site of DNA hydrolysis by the ,,lsulI restriction en- 
zyme. Vertical arrow shows the presumed location of the site of pre-protein's ignal peptide splitting off. 
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rate obtained was dissolved in 6 M carbomide, centrifuged, and the 
supernatant was applied on a column with Sephacryl S-200. Fractions 
containing the target protein and the rate of its being pure were 
analysed electrophoretically [9].The fractions containing the target 
protein were combined, iluted 5 times with cold PBS buffer, dialysed 
against the same buffer for 15 to 18 h, centrifuged, and the super- 
natant was filtrated through a sterilising filter. The protein's concen- 
tration was determined bythe method escribed in [10] while using a 
kit by Bio-Rad Laboratories Co. (USA). 
2..5. Analysis of recombinant proteins pecific activity 
The recombinant viral proteins were studied for specific activity by 
the modified method of interferon-neutralising antibodies evaluation 
[11] where plate wells with the L-68 cell culture got introduced serial 
dilutions of samples under study (previously standardised considering 
the recombinant proteh~'s concentrations) in Eagle's minimum essen- 
tial medium (Eagle's MEM), and human v.IFN was added up to final 
concentration 10IUIml. After 24 h of incubation at 37°C, the culture 
medium was removed from the wells, the cell monolayer was washed 
three times with Eagle's MEM, and a challenge virus (murine nce- 
phalomyocarditis virus) was introduced as described [11]. After 24 h, 
results were valuated and interferon-neutralising activity of recombi- 
nant viral proteins was determined asdescribed [11]. Simultaneously, 
biological activity of y-IFN used was monitored as described above. 
3. Results and discussion 
Amino acid sequences of ~IFN receptor-like proteins of the 
two strains under study, variola major and variola minor 
viruses, show high homology. The protein from the IND 
strain bears Thr, Glu, Gly and Thr in positions 7, 110, 113, 
and 208, respectively, while the corresponding protein from 
the GAR strain has in these positions Pro, Lys, Asp, Ser, 
respectively (Fig. 1). To answer the question whether point 
substitutions are able to considerably influence the presumed 
specific activity of the viral proteins, one has to isolate the 
corresponding proteins individually. At present here is only 
one method available as to how to obtain the VAR proteins 
under study: construction of genetically engineered producer 
strains of the target proteins. 
To achieve expression of the target viral ORFs, hybrid 
plasmids pRIRgT and pRIRinT were constructed (Fig. 2). 
Those plasmids were created by cloning in the pRTUi e~pres- 
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Fig. 2. Scheme of hybrid plasmids pRIRI,T×pRIRsT containing 
target gene of IND and GAR, respectively. Sequence of synthetic 
duplex providing joining of the recA promoter fragment to the 
structural part of the gene of the ¥-IFN receptor-like protein mature 
form (Fig. 1), is shown at the bott,~m. Translation i itiating triplet 
ATG is given in bold type. 
sion vector a corresponding fragment of the viral DNA with 
the target ORF ligated with the phosphorylated synthetic 
DNA duplex containing a translation initiating triplet 
(ATG) (F~g. 2). 
The structure of the hybrid plasmids is so that the target 
gene transcription is initiated at the inducible promoter of the 
recA Proteus mirabilis gene [8] and stopped at the p-indepen- 
dent terminator of the E. coil trpA gene (Fig. 2). The coding 
sequence of the inserted target viral ORF determines the ma- 
ture form of the ¥-IFN receptor-like protein without 16 N- 
terminal amino acid residues of the signal peptide (Figs. 1 and 
2). The hybrid plasmids pRIRgT and pRIRinT were used to 
transform cells of the E. coli strains JM103, BL21, VLI201, 
VL1222, and production of the recombinant proteins was 
analysed. The target protein accumulated in bacterial cells in 
the inclusion bodies and then was dissolved in 6 M carbomide 
(Fig. 3a). This allowed to rather simply isolate it from the 
cellular biomass by using consecutive washing the inclusion 
bodies, dissolving the target protein in 6 M carbomide, gel 
filtration, and dialysis (Fig. 3b). Molecular weight of the ex- 
pression product (approximately 30 kDa) was close to the 
predicted one. The E. coli strains VLI201, VL1222 and 
BL21 should be noted to show, though they have a decreased 
ability of intracellular proteolysis, no considerable differences 
from the JM103 strain with regard to the recombinant viral 
protein production level determined by densitometry: 12% to 
15% of the total cellular protein as regards the two former 
strains, and 10% to 12% of the total cellular protein as regards 
the two latter strains. 
In the course of three independent analyses of the purified 
recombinant viral proteins pecific activity, the interferon-neu- 
tralising activity of the IND strain's recombinant viral protein 
was determined as (4.0+2.0)x 105 U/mg, and that of the 
GAR strain (2.5+_1.5)x105 U/mg, i.e. these magnitudes of 
the proteins compared practically do not differ. Considering 
that antiviral activity of the recombinant human ¥-IFN (Sig- 
ma) was 107 IU/mg, and as 1 activity unit of the recombinant 
viral protein is a minimum of its amount was taken which 
caused a complete antiviral activity inhibition of 1 IU of V- 
IFN, one can conclude that the recombinant viral proteins 
homologous to the human ~.IFN receptor show a relatively 
high intcrferon-neutralising activity. 
The results obtained suggest hat glycosylation of the viral 
proteins homologous to the ¥-IFN receptor does not consid- 
erabiy influence the manifestation of their specific activity. 
Antiviral activity inhibition was not observed when recombi- 
nant human a-IFN (10 IU/ml) was used instead of ¥-IFN: 
with recombinant viral proteins concentration of 1 pg/ml, a- 
IFN revealed 100% antiviral activity. This testifies to strict 
specificity of the recombinant viral proteins activity with re- 
gard to ¥-IFN, one of the most important cytokines partici- 
pating in formation of the organism's protective mechanisms 
against infectious agents [3,12-14]. 
It should be noted that activity of the highly virulent IND 
strain's recombinant protein of VAR does not differ from that 
of the low-virulent GAR strain. These data allow us to con- 
clude that differences in virulence rate of different VAR 
strains are determined by other viral genes or complex of 
genes. 
Variola virus restricted, in the course of evolution, the 
range of sensitive animals with only one species: Homo sa- 
piens [15]. That would suggest that mechanisms ofmodulation 
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Fit;. 3. Production of the recombinant viral proteins homologous tothe human y-IFN receptor in the £. coli VLI222 cells. Analysis of samples 
by SDS.PAGE (15% separation gel) and Coomassie blue staining of the gel. a: iocalisation of recombinant proteins in £. coil cells. Lanes I to 
3, soluble cellular proteins; lanes 4 to 6, insoluble cellular proteins (inclusion bodies). Lanes i and 4, corresp,md topRIRgT-bearing cells, in- 
du~,d by mitomycln C, lanes 2 and 5 to those with plasmid pltlRinT, and lane~ 3 and 6 to those without plasmid; b: recombinant viral pro- 
reins, isolated from the inclusion bodies and then purified, being coded by plasmid pRIRtnT or pRIRgT (lanes 3 and 4, respectively). Lanes 1 
and 2, marker proteins with molecular weight of 29 and 14 kDa, respectively. 
of the host organism protective responses by variola virus 
adapted themselves evolutionarily and specifically to the cor- 
responding systems of humans. To verify this presumption, 
besides human ~IFN, murine ~IFN was also analysed. 
We used a dose of VAR recombinant proteins homologous 
to y-IFN receptor which completely inhibited antiviral activity 
of the recombinant human y-IFN in a concentration of 250 
IU/ml in the L-68 cell culture. Al~er that, those samples of 
VAR proteins were studied for their ability to suppress the 
recombinant routine y-IFN antiviral activity in the routine 
fibroblasts Lm cell culture. The recombinant viral proteins 
were established to be unable, in the chosen dose, to inhibit 
the routine y-IFN antiviral activity even when the latter had a 
concentration of 4 IU/ml, The data obtained show that the 
VAR proteins under study can actively interact with human 7- 
IFN but no*+ with routine V-IFN. Similar data have been re- 
ported recently for the y-IFN-binding protein of vaceinia virus 
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